Status: current, Sufficiently defined by necessary conditions definition status. Date: 31-Jul 2019. Module: SNOMED CT core module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3758687011 | Product containing precisely pazopanib (as pazopanib hydrochloride) 400 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive | SNOMED CT core module |
| 3758688018 | Pazopanib (as pazopanib hydrochloride) 400 mg oral tablet | en | Synonym | Active | Entire term case insensitive | SNOMED CT core module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely pazopanib (as pazopanib hydrochloride) 400 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | Conventional release oral tablet | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely pazopanib (as pazopanib hydrochloride) 400 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 400 | false | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely pazopanib (as pazopanib hydrochloride) 400 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Pazopanib hydrochloride | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely pazopanib (as pazopanib hydrochloride) 400 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance | Pazopanib | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely pazopanib (as pazopanib hydrochloride) 400 milligram/1 each conventional release oral tablet (clinical drug) | Has unit of presentation | Tablet | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely pazopanib (as pazopanib hydrochloride) 400 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Product containing only pazopanib in oral dose form (medicinal product form) | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely pazopanib (as pazopanib hydrochloride) 400 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit | Tablet | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely pazopanib (as pazopanib hydrochloride) 400 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | 1 | false | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely pazopanib (as pazopanib hydrochloride) 400 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit | milligram | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely pazopanib (as pazopanib hydrochloride) 400 milligram/1 each conventional release oral tablet (clinical drug) | Count of base of active ingredient | 1 | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely pazopanib (as pazopanib hydrochloride) 400 milligram/1 each conventional release oral tablet (clinical drug) | Plays role | Antineoplastic therapeutic role | true | Inferred relationship | Existential restriction modifier |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR